Without pharmacokinetic data on sublingual tirzepatide absorption patterns, there is no scientific basis to recommend one dosing frequency over another
The workaround many prescribers use: if a non-diabetic patient also has a comorbidity that a GLP-1 drug treats (cardiovascular disease for Wegovy, sleep apnea for Zepbound), the prescriber can request coverage under that indication
HSA/FSA eligible Financing options available Convenient video visits from home with experienced medical providers GLP-1 Medications & Telehealth Program Pricing We believe telehealth medical weight loss should be transparent and accessible
[6] Vujacic, M., Marinkovic, M., Radosavljevic, J., et al
April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
This is why it is typically viewed as a safe medication for donors, provided the donor feels healthy